Evidence map›Paper›PMID 41069369›Full record

ArticleRSC advances2025

Synthesis, biological evaluation, and docking analysis of novel benzimidazole-triazole hybrids as potential anticancer agents.

Amir Shervin Shokouhi Asl, Sara Ranjbar, Mohammad Hosein Sayahi, Zahra Dehghani, Amir Mohammad Taherkhani, Manica Negahdaripour, Navid Dastyafteh, Mina Emami, Sajedeh Safapoor, Abbas Ghahramani and 4 more

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Amir Shervin Shokouhi AslDepartment of Medicinal Chemistry, School of Pharmacy, Iran University of Medical Sciences Tehran Iran.ORCID https://orcid.org/0009-0007-6970-4523
Sara RanjbarPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences Shiraz Iran ghasemiy@sums.ac.ir.ORCID https://orcid.org/0000-0002-7675-4146
Mohammad Hosein SayahiDepartment of Chemistry, Payame Noor University Tehran Iran.
Zahra DehghaniPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences Shiraz Iran ghasemiy@sums.ac.ir.
Amir Mohammad TaherkhaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran momahdavi@tums.ac.ir.
Manica NegahdaripourPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences Shiraz Iran ghasemiy@sums.ac.ir.ORCID https://orcid.org/0000-0002-4265-1499
Navid DastyaftehEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran momahdavi@tums.ac.ir.
Mina EmamiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences Shiraz Iran ghasemiy@sums.ac.ir.
Sajedeh SafapoorEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran momahdavi@tums.ac.ir.
Abbas GhahramaniDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Kerman University of Medical Sciences Kerman Iran.
Mohammad Reza Mohajeri-TehraniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran momahdavi@tums.ac.ir.
Bagher LarijaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran momahdavi@tums.ac.ir.
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran momahdavi@tums.ac.ir.
Younes GhasemiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences Shiraz Iran ghasemiy@sums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of novel benzimidazole-triazole acetamide hybrids with different substitutions at the acetamide moiety were designed and synthesized in an effort to discover potential anticancer agents. The compounds were evaluated for their

Identifiers

PMID41069369
PMCPMC12506886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.